Program Evaluation
*
LowBelow AverageAverageAbove AverageHigh
Christopher P. Evans, MD, FACS
Laurence Klotz, MD, FRCS(C)
Format
Program Materials
Level of Interaction
*
Strongly DisagreeDisagreeNeutralAgreeStrongly Agree
Compare and contrast different delivery technologies and methods of LHRH agonist administration, especially subcutaneous injection vs. intramuscular administration
Discuss the pharmacokinetic profile of different ADTs and impact of more consistent drug delivery on patient outcomes
Discuss the clinical significance of testosterone suppression to lower levels <20ng/dL
Define the practice of switching between ADTs
Discuss clinical evidence supporting new innovations in advanced prostate cancer treatment, especially among LHRH agonists
*
Strongly DisagreeDisagreeNeutralAgreeStrongly Agree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CME activities in which I have participated in the last 12 months
There is a continuing need for education on this topic
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*